Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-18T23:10:14.526Z Has data issue: false hasContentIssue false
  • English
  • Français

Efecto de la carbamacepina sobre la agitación y labilidad emocional asociadas con demencia grave

Published online by Cambridge University Press:  12 May 2020

M. R. Lemke
M. R. Lemke*
Affiliation:
Departamento de Psiquiatría, Centro Médico Ingolstadt, Krumenauerstr 25, D-85049Ingolstadt, Alemania
Get access

Resumen

En un estudio prospectivo abierto, se investigaron los efectos estabilizadores de la carbamacepina sobre la agitación, impulsividad y labilidad afectiva en 15 pacientes con demencia grave que no habían respondido a medicación anterior con neurolépticos. El tratamiento de carbamacepina se interrumpió en dos sujetos debido a leucopenia y reacciones alérgicas. En nueve pacientes se observó una mejoría clínica importante.

Keywords

carbamacepinaagitacióndemenciazotepina
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 2 , Issue 6 , December 1995 , pp. 400 - 405
Copyright
Copyright © European Psychiatric Association 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografia

Ackenheil, MThe biochemical action profile of zotepine compared with that of other neuroleptics. Fortschr Neurol Psychiatr 1991; 59 (suppl 1): 2–9.CrossRefGoogle Scholar
Ballenger, JCThe clinical use of carbamazepine in affective disorders. J Clin Psychiatry 1988; 49 (suppl 4): 13–19.Google ScholarPubMed
Dieterle, DMAckenheil, MMuller-Spahn, FKapfhammer, HPZotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry 1987; 20 (suppl 1): 52–8.CrossRefGoogle ScholarPubMed
Dose, MApelt, SEmrich, HMCarbamazepine as adjunct of antipsychotic therapy. Psychiatry Res 1987; 2: 23–4.Google Scholar
Essa, MCarbamazepine in dementia. J Clin Psychopharmacol 1986; 6: 234–6.CrossRefGoogle ScholarPubMed
Finzen, ACarbamazepine in the treatment of mania and prevention of relapses in affective disorders. Psychiatr Prax 1991; 18: 1–8.Google Scholar
Folstein, MFolstein, SMcHugh, PRMini-Mental State: a practical method for grading the cognitive State of patients for the clinical. J Psychiatr Res 1975; 12: 189–98.CrossRefGoogle Scholar
Gaitz, CMVarner, RVOverall, JEPharmacotherapy for organic brain syndrome in late life. Arch Gen Psychiatry 1977; 34: 839–45.CrossRefGoogle ScholarPubMed
Gardner, DLCowdry, RWPositive effects of carbamazepine on behavioral dyscontrol in borderline personality. Am J Psychiatry 1986; 143: 519–22.Google ScholarPubMed
Gleason, RPSchneider, LSCarbamazepine treatment of agitation in Alzheimer’s outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51:115–8.Google ScholarPubMed
Heath, RGStudies with deep electrodes in patients intractable ill with epilepsy and other disorders. In: Trimble, MRReynolds, EH, eds. What is epilepsy? Edipgbourgh: Churchill Livingston, 1986; 126–32.Google Scholar
Helmchen, HKanowski, SKoch, HGResearch with demented patients: need for research and the problem of informed consent. Ethik Med 1989; 1: 83–98.Google Scholar
Jann, MWEreshefsky, LSaklad, SRet al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5: 106–9.CrossRefGoogle ScholarPubMed
Kane, JMSmith, JMTardive dyskinesia. Arch Gen Psychiatry 1982; 39: 473–81.CrossRefGoogle ScholarPubMed
Lemke, MRTherapeutic effect of carbamazepine on affective liability and agitation associated with dementia. Neuropsychopharmacol 1993; 9 (suppl 2): 126.Google Scholar
Lemke, MRCarbamazepine treatment of agitated dementia. Münch Med Wschr 1994; 136: in press.Google Scholar
Marin, DBGreenwald, BSCarbamazepine for aggressive agitation in demented patients during nursing care. Am J Psychiatry 1989; 146: 805.Google ScholarPubMed
O’Dougherty, MWright, FSCox, SWalson, PCarbamazepine plasma concentration relationship to cognitive impairment. Arch Neurol 1987; 44: 863–7.CrossRefGoogle ScholarPubMed
Patterson, JFCarbamazepine for assaultive patients with organic brain disease. Psychosomatics 1987; 28: 581–97.CrossRefGoogle ScholarPubMed
Post, RMMechanisms of action carbamazepine and related anti-convulsants in affective illness. In: Meltzer, HY, et. Psychopharmacology: A Generation ofProgress. New York: Raven Press, 1987; 567–76.Google Scholar
Post, RMSusan, RWeiss, BSensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiat 1992; 25: 41–3.CrossRefGoogle ScholarPubMed
Reisberg, BBorenstein, JSalob, SPBehavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 (suppl): 9–15.Google ScholarPubMed
Shader, RIHarmatz, JSSalzman, CA new scale for clinical assessment on geriatric populations: Sandoz Clinical Assessment-Geriatric. J Am Geriatr Soc 1974; 22: 107–13.CrossRefGoogle ScholarPubMed
Schneider, LSPollok, VELyness, SAA metaanalysis of controlled triais of neuroleptic treatment in dementia. JAm Geriatr 1990; 38: 553–63.CrossRefGoogle Scholar
Siever, LTrestman, RLThe serotonin system and aggressive personality disorder. Int Clin Psychopharmacol 1993; 8 (suppl 2): 33–9.CrossRefGoogle ScholarPubMed